✓ Luottokorttimaksut palautettu — turvallinen kassaprosessi Privacy Shieldin kautta

Ambrican

Ambrican is ambrisentan 5 mg tablets — selective endothelin-A receptor antagonist for pulmonary arterial hypertension (PAH). Originally Letairis/Volibris (Gilead/GSK 2007). ARIES-1/2 trials established PAH benefit; AMBITION (2015) supported upfront combination therapy with tadalafil. Less hepatotoxic than bosentan. PAH is specialist-managed, not ordinary systemic hypertension — all ERAs are strictly contraindicated in pregnancy (REMS programme in US).

Lääketieteellinen tarkistus Morgan Ellis — Farmasian tutkija · 8 vuoden kokemus  · Viimeisin arvio: toukokuu 2026

Salattu kassavaihe
Kryptomaksut 10% halvempia
Hienovaraiset maailmanlaajuiset toimitukset
1 400+ asiakasta · 50+ maata

Tämä tuote on tällä hetkellä loppu varastosta eikä saatavilla.

⚡ Quick Answer — What is Ambrican?

Ambrican is 5 mg ambrisentan tablets from a WHO-GMP certified manufacturer — a selective endothelin receptor A antagonist (ERA) for pulmonary arterial hypertension (PAH). PAH is a specific, progressive, and rare disease — not the same as systemic hypertension. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Ambrisentan was introduced by Gilead/GSK in 2007 as Letairis (US) / Volibris (global). Selective for ETA over ETB receptors — theoretical advantage of preserving the ETB-mediated clearance and vasodilator pathway, though clinical superiority over non-selective ERAs (bosentan, macitentan) has not been definitively demonstrated. selectively blocks endothelin-A receptors on pulmonary arterial smooth muscle. Endothelin-1 is a potent vasoconstrictor and pro-fibrotic mediator upregulated in PAH; ERA blockade reduces pulmonary vascular resistance and pulmonary artery pressure, and slows disease progression. Dosing: Start 5 mg once daily; increase to 10 mg once daily at 4 weeks if tolerated. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.

Mitä saat MedsBasen kautta: WHO-GMP sertifioitu valmistaja · Hienotunteinen pakkaus · Maailmanlaajuinen toimitus · 1 400+ varmennettua asiakasarviota

📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.

Miksi tilata MedsBasesta

Geneeriset lääkkeemme on hankittu WHO-GMP sertifioiduilta valmistajilta ja toimitettu maailmanlaajuisesti hienotunteisessa, neutraalissa pakkauksessa — lääkkeen nimeä ei ole pakkauksen ulkopuolella. Korttimaksut käsitellään säädeltyjen maksunvälittäjien kautta (tilisiirtojen kuvaukset sisältävät säädellyn korttimaksun käsittelijän — ei koskaan “MedsBase” tai lääkkeen nimeä). Kryptovaluutat ja SEPA-pankkisiirrot hyväksytään myös. Jokainen tilaus on turvattu meidän Reshipment Assurance Policy -takuuohjelmalla.

What Is Ambrican?

Ambrican is 5 mg ambrisentan tablets from a WHO-GMP certified manufacturer, supplied in 30-90 tablets. Ambrisentan was introduced by Gilead/GSK in 2007 as Letairis (US) / Volibris (global). Selective for ETA over ETB receptors — theoretical advantage of preserving the ETB-mediated clearance and vasodilator pathway, though clinical superiority over non-selective ERAs (bosentan, macitentan) has not been definitively demonstrated.

Pulmonary arterial hypertension (PAH) is not systemic hypertension. PAH refers specifically to raised pressure in the pulmonary arterial circulation (≥20 mmHg mean pulmonary arterial pressure with pulmonary vascular resistance ≥2 Wood Units per 2022 ESC/ERS guidelines). It is rare (estimated 15-50 per million adults), progressive, and without treatment carries a poor prognosis (historical 5-year survival ∼30%). Modern PAH-targeted therapy has improved 5-year survival to 60-70% in expert centres.

Candidates for Ambrican have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.

How Ambrisentan Works

Selectively blocks endothelin-A receptors on pulmonary arterial smooth muscle. Endothelin-1 is a potent vasoconstrictor and pro-fibrotic mediator upregulated in PAH; ERA blockade reduces pulmonary vascular resistance and pulmonary artery pressure, and slows disease progression.

Evidence

ARIES-1 and ARIES-2 (2008) — ambrisentan in 202 and 192 PAH patients respectively; 6-minute walk improved by 31-51 m vs placebo; WHO functional class improved; clinical worsening delayed. AMBITION (2015) — upfront ambrisentan + tadalafil reduced clinical failure by 50% vs either as monotherapy in treatment-naive PAH, establishing combination initial therapy as standard of care for moderate-severe PAH.

Dosage and Monitoring

Dosing: Start 5 mg once daily; increase to 10 mg once daily at 4 weeks if tolerated.

Seuranta: at baseline and every 3-6 months thereafter — WHO functional class, 6-minute walk distance, NT-proBNP, repeat echocardiography, and (at longer intervals) right heart catheterisation. All done through a specialist PAH centre.

Liver function: baseline LFTs, then every 1-3 months initially, then every 3-6 months. Discontinue if transaminases >3× ULN with symptoms or >5× ULN asymptomatic.

Haittavaikutukset

  • Peripheral oedema (17-30%; higher than other ERAs)
  • Hepatotoxicity (<1% with ambrisentan — lower than bosentan; LFT monitoring is less intensive than with bosentan)
  • Anaemia — class effect
  • Nasal congestion, flushing, headache
  • Testicular atrophy and reduced sperm count (rare class effect)
  • Pulmonary veno-occlusive disease unmasking — can precipitate life-threatening pulmonary oedema in misdiagnosed PVOD; assess carefully before starting.

Käyttökiellot

  • Pregnancy — absolute contraindication. All ERAs are teratogenic (craniofacial and cardiovascular malformations). US: REMS programme with monthly pregnancy testing and dual contraception; global: similar risk management programmes.
  • Idiopathic pulmonary fibrosis (ERAs worsen IPF)
  • Vakava maksan vajaatoiminta (Child-Pugh B tai C)

Usein Kysytyt Kysymykset

Is pulmonary arterial hypertension the same as “high blood pressure”?

No. Systemic hypertension is raised pressure in the general circulation and is very common; PAH is raised pressure in the pulmonary circulation specifically and is rare. They have different causes, different specialists (PAH care is typically by pulmonology/cardiology teams at tertiary centres), and very different drug treatments. A drug that lowers systemic BP (ACEi, ARB, CCB, thiazide) usually has little effect on PAH.

Why does Ambrican require specialist monitoring?

PAH is a specialist-managed disease with a registry-based surveillance model in most countries. The drugs are expensive, have specific adverse effects (particularly hepatotoxicity for ERAs and hypotension for sGC stimulators), and dose-titration depends on serial assessments (6-minute walk, functional class, NT-proBNP, echocardiography). Off-label self-management carries high risks of clinical deterioration.

Can I take Ambrican with erectile dysfunction drugs?

Yes with caution. Ambrisentan + PDE5 inhibitor (sildenafil, tadalafil) is actually the AMBITION combination — standard of care for moderate-severe PAH. However, BP monitoring is important because both drugs lower systemic BP.

Can I take Ambrican in pregnancy?

Ei. All endothelin receptor antagonists are teratogenic (craniofacial and cardiovascular malformations). Monthly pregnancy testing and dual contraception are required during therapy; the same precautions are standard for bosentan and macitentan.

Where can I buy Ambrican online?

You can buy Ambrican (ambrisentan 5 mg, 30-90 tablets) from MedsBase with discreet packaging and worldwide shipping.

Related Cardiovascular Medications

⚕ Lääketieteellinen vastuuvapauslauseke. This page is for informational purposes only and does not replace medical advice from a qualified healthcare professional. Hypertension, heart failure, and arrhythmias require diagnosis, monitoring, and dose individualisation by a doctor — always use beta-blockers under medical guidance.

Hinta-alue: 9,00 USD - 36,00 USD

Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.

Vahvuus

5 mg

Määrä

30 tablettia, 60 tablettia, 90 tablettia

Lääkemuoto

Tabletti/tabletteja

Valmistaja

Lupin Ltd

Hoito

Keuhkovaltimoiden hypertensio (PAH)

Geneerinen tuotemerkki

Ambrisentan

Arvostelut

Ei vielä arvosteluja

Lisää arvostelu
Ambrican Ambrican
Arvosana*
0/5
* Arvosana vaaditaan
* Vastaus vaaditaan
Arvostelusi
* Arvostelu vaaditaan
Nimi
* Nimi on pakollinen
Lisää kuvia tai video arvosteluusi

Kysymykset ja vastaukset

Esitä kysymys
Ambrican Ambrican
Kysymyksesi
* Kysymys on pakollinen
Nimi
* Nimi on pakollinen
Ei vielä kysymyksiä